<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566525</url>
  </required_header>
  <id_info>
    <org_study_id>2015-001</org_study_id>
    <nct_id>NCT02566525</nct_id>
  </id_info>
  <brief_title>CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery</brief_title>
  <acronym>REFRESH</acronym>
  <official_title>CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoSorbents, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoSorbents, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, randomized, feasibility clinical study. Subjects will be&#xD;
      randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and&#xD;
      treatment with the CytoSorbÂ® device.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Serious Device Related Adverse Events</measure>
    <time_frame>From time of enrollment through ICU discharge (e.g. ICU stay of approximately 4 days)</time_frame>
    <description>The primary safety endpoint of this trial was to determine the product safety profile through the assessment of serious device related AEs through discharge from the ICU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in the ICU</measure>
    <time_frame>From the end of cardiopulmonary bypass procedure through ICU discharge (e.g. ICU stay of approximately 4 days)</time_frame>
    <description>Days in ICU, Post Surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Day All Cause Mortality</measure>
    <time_frame>From time of enrollment through 30 days post procedure</time_frame>
    <description>Mortality within 30 Days of Surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Rates</measure>
    <time_frame>through 30 days</time_frame>
    <description>Total number of Serious Adverse Events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Complement Factor C3a - 2 Hours Post Start of CPB</measure>
    <time_frame>2 hours post start of cardiac bypass</time_frame>
    <description>Change in complement factor C3a - Sampling at 2 hours post start of CPB</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Complement Factor C3a - 3 Hours Post Start of CPB</measure>
    <time_frame>3 hours post start of CPB</time_frame>
    <description>Change in complement factor C3a - Sampling at 3 hours post start of CPB</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Complement Factor C5a - 2 Hours Post Start of CPB</measure>
    <time_frame>2 hours post start of cardiac bypass</time_frame>
    <description>Change in complement factor C5a - Sampling at 2 hours post start of CPB, change from baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Elective Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>CytoSorb Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care plus treatment with CytSorb device installed on the CPB machine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb</intervention_name>
    <description>Cytosorb device use during cardiopulmonary bypass</description>
    <arm_group_label>CytoSorb Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective, cardiac surgery requiring cardiopulmonary bypass with anticipated duration&#xD;
             of &gt;180 minutes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Platelet count &lt; 20,000/ uL&#xD;
&#xD;
          -  Body mass index &lt;18&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Life expectancy of &lt;14 days&#xD;
&#xD;
          -  End stage organ disease&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Undergoing cardiac transplant or ventricular assist device explant, isolated primary&#xD;
             coronary artery bypass grafting (CABG) or single valve procedure&#xD;
&#xD;
          -  Contraindication to anticoagulation with heparin&#xD;
&#xD;
          -  Declined informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Sisk, MSc Pharm</last_name>
    <role>Study Director</role>
    <affiliation>CytSorbents</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <results_first_submitted>May 20, 2019</results_first_submitted>
  <results_first_submitted_qc>July 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2021</results_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CytoSorb device</keyword>
  <keyword>Plasma free hemoglobin</keyword>
  <keyword>inflammation</keyword>
  <keyword>extracorporeal bypass</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient In; 8 December, 2015 Last Patient in: 19 August 2016&#xD;
Mostly university hospitals; all sites had robust cardiac surgery programs</recruitment_details>
      <pre_assignment_details>Potential patients had to have a planned 3+ hour bypass time. Isolated coronary bypass graft or single valve procedures were excluded. Cases included were aortic reconstructions, valve repairs, valve replacements and combinations thereof, and permitted combination with coronary bypass graft. Emergency and endocarditis patients were excluded. 52 patients enrolled in the study, of which 6 withdrew from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CytoSorb Device</title>
          <description>Standard of care cardiac surgery with CPB plus treatment with CytSorb device installed on the CPB machine&#xD;
CytoSorb: Cytosorb device use during cardiopulmonary bypass</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Standard of care, cardiac surgery patients, cardiac bypass with no CytoSorb device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23">FPI - CytoSorb Patient 15 Jan 2016</participants>
                <participants group_id="P2" count="23">FPI - Control Patient 8 Dec 2015</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20">LPI - CytoSorb Patient 19 Aug 2016</participants>
                <participants group_id="P2" count="18">LPI - Control 16 Aug 2016</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CytoSorb Device</title>
          <description>Standard of care plus treatment with CytSorb device installed on the CPB machine&#xD;
CytoSorb: Cytosorb device use during cardiopulmonary bypass</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Standard of care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.09" spread="7.91"/>
                    <measurement group_id="B2" value="61.09" spread="16.77"/>
                    <measurement group_id="B3" value="63.59" spread="13.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Serious Device Related Adverse Events</title>
        <description>The primary safety endpoint of this trial was to determine the product safety profile through the assessment of serious device related AEs through discharge from the ICU.</description>
        <time_frame>From time of enrollment through ICU discharge (e.g. ICU stay of approximately 4 days)</time_frame>
        <population>All patients who had at least on Adverse Event</population>
        <group_list>
          <group group_id="O1">
            <title>CytoSorb Device</title>
            <description>Standard of care cardiac surgery with CPB plus treatment with CytSorb device installed on the CPB machine&#xD;
CytoSorb: Cytosorb device use during cardiopulmonary bypass</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care, cardiac surgery patients, cardiac bypass with no CytoSorb device</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Serious Device Related Adverse Events</title>
          <description>The primary safety endpoint of this trial was to determine the product safety profile through the assessment of serious device related AEs through discharge from the ICU.</description>
          <population>All patients who had at least on Adverse Event</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least one device related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with at least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in the ICU</title>
        <description>Days in ICU, Post Surgery</description>
        <time_frame>From the end of cardiopulmonary bypass procedure through ICU discharge (e.g. ICU stay of approximately 4 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CytoSorb Device</title>
            <description>Standard of care cardiac surgery with CPB plus treatment with CytSorb device installed on the CPB machine&#xD;
CytoSorb: Cytosorb device use during cardiopulmonary bypass</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care, cardiac surgery patients, cardiac bypass with no CytoSorb device</description>
          </group>
        </group_list>
        <measure>
          <title>Time in the ICU</title>
          <description>Days in ICU, Post Surgery</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="3.34"/>
                    <measurement group_id="O2" value="6.82" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Day All Cause Mortality</title>
        <description>Mortality within 30 Days of Surgery</description>
        <time_frame>From time of enrollment through 30 days post procedure</time_frame>
        <population>All patients who were randomized to trial and had a surgical procedure</population>
        <group_list>
          <group group_id="O1">
            <title>CytoSorb Device</title>
            <description>Standard of care cardiac surgery with CPB plus treatment with CytSorb device installed on the CPB machine&#xD;
CytoSorb: Cytosorb device use during cardiopulmonary bypass</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care, cardiac surgery patients, cardiac bypass with no CytoSorb device</description>
          </group>
        </group_list>
        <measure>
          <title>30 Day All Cause Mortality</title>
          <description>Mortality within 30 Days of Surgery</description>
          <population>All patients who were randomized to trial and had a surgical procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Rates</title>
        <description>Total number of Serious Adverse Events</description>
        <time_frame>through 30 days</time_frame>
        <population>Total number of Serious Adverse Events</population>
        <group_list>
          <group group_id="O1">
            <title>CytoSorb Device</title>
            <description>Standard of care cardiac surgery with CPB plus treatment with CytSorb device installed on the CPB machine&#xD;
CytoSorb: Cytosorb device use during cardiopulmonary bypass</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care, cardiac surgery patients, cardiac bypass with no CytoSorb device</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Rates</title>
          <description>Total number of Serious Adverse Events</description>
          <population>Total number of Serious Adverse Events</population>
          <units>SAE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Complement Factor C3a - 2 Hours Post Start of CPB</title>
        <description>Change in complement factor C3a - Sampling at 2 hours post start of CPB</description>
        <time_frame>2 hours post start of cardiac bypass</time_frame>
        <population>Patients with evaluable C3a laboratories</population>
        <group_list>
          <group group_id="O1">
            <title>CytoSorb Device</title>
            <description>Standard of care plus treatment with CytSorb device installed on the CPB machine&#xD;
CytoSorb: Cytosorb device use during cardiopulmonary bypass</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Complement Factor C3a - 2 Hours Post Start of CPB</title>
          <description>Change in complement factor C3a - Sampling at 2 hours post start of CPB</description>
          <population>Patients with evaluable C3a laboratories</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1146.75" spread="383"/>
                    <measurement group_id="O2" value="3116.24" spread="4008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Complement Factor C3a - 3 Hours Post Start of CPB</title>
        <description>Change in complement factor C3a - Sampling at 3 hours post start of CPB</description>
        <time_frame>3 hours post start of CPB</time_frame>
        <population>Patients with evaluable C3a laboratory values at 3 hours post start of CPB</population>
        <group_list>
          <group group_id="O1">
            <title>CytoSorb Device</title>
            <description>Standard of care plus treatment with CytSorb device installed on the CPB machine&#xD;
CytoSorb: Cytosorb device use during cardiopulmonary bypass</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Complement Factor C3a - 3 Hours Post Start of CPB</title>
          <description>Change in complement factor C3a - Sampling at 3 hours post start of CPB</description>
          <population>Patients with evaluable C3a laboratory values at 3 hours post start of CPB</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2491.1" spread="1339"/>
                    <measurement group_id="O2" value="1234.67" spread="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Complement Factor C5a - 2 Hours Post Start of CPB</title>
        <description>Change in complement factor C5a - Sampling at 2 hours post start of CPB, change from baseline</description>
        <time_frame>2 hours post start of cardiac bypass</time_frame>
        <population>Patients with evaluable C5a laboratories</population>
        <group_list>
          <group group_id="O1">
            <title>CytoSorb Device</title>
            <description>Standard of care plus treatment with CytSorb device installed on the CPB machine&#xD;
CytoSorb: Cytosorb device use during cardiopulmonary bypass</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Complement Factor C5a - 2 Hours Post Start of CPB</title>
          <description>Change in complement factor C5a - Sampling at 2 hours post start of CPB, change from baseline</description>
          <population>Patients with evaluable C5a laboratories</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.29" spread="11.9"/>
                    <measurement group_id="O2" value="0.18" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported for the 30 day period following Cardiac Surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CytoSorb Device</title>
          <description>Standard of care cardiac surgery with CPB plus treatment with CytSorb device installed on the CPB machine&#xD;
CytoSorb: Cytosorb device use during cardiopulmonary bypass</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Standard of care, cardiac surgery patients, cardiac bypass with no CytoSorb device</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Medra 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra">Atrial Fibrilation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Myocardial stunning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Acute Lung Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Medra 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Atrial Fibrilation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tranaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Atalectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joseph Zwischenberger, MD</name_or_title>
      <organization>University of Kentucky College of Medicine</organization>
      <phone>859-323-6013</phone>
      <email>jzwis2@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

